Recruiting

Evaluation of Phacogoniotomy in Medically-controlled POAG

The goal of this multicenter non-inferiority randomized controlled trial is to compare the efficacy of phacoemulsification with intraocular lens implantation (PEI) combined with goniotomy (GT) and PEI combined with medical therapy (MED) in the treatment of medically-controlled primary open-angle glaucoma (POAG) with cataract. The main questions it aims to answer are: * Whether the PEI+GT was non-inferior to PEI+MED with regard to the intraocular pressure lowering effect in medically-controlled POAG. * Whether the…

ClinicalTrials.gov IDNCT06201455

PhaseNA

Enrollment100

SponsorSun Yat-sen University

Age40 Years

SexALL

I'm interested View official listing

Conditions studied

Glaucoma, Open-Angle, Cataract Complicated, Goniotomy

About this study

Interventions

Procedure: PEI+GT — After a standard phacoemulsification with intraocular lens implantation (PEI) is performed. The viscoelastic substance will be injected into the anterior chamber again to maintain corneal rigidity. The surgical microscope will be adjusted to tilt 35-40° towards the patient's nasal side, and the patient's head position will be adjusted to tilt 35-40° accordingly. A viscoelastic substance will be applied to the corneal surface to facilitate direct visualization of the angle structures under a gonioscope. The Tanito Microhook will be inserted through the main incision into the anterior chamber, and under gonioscopic guidance, the nasal (or inferonasal) trabecular meshwork and the inner wall of Schlemm's canal will be incised, approximately 120° in extent (60° in each direction).
Procedure: PEI+MED — Participants assigned to control group will undergo routine PEI surgery. Postoperatively, the decision to administer anti-glaucoma medication is based on intraocular pressure (IOP) measurements, and the target IOP is set at 16 mmHg. The selection of medications is informed by the Asia Pacific Glaucoma Guidelines (Kugler Publications, 2016), while the target IOP reference is the European Glaucoma Guidelines.

Primary outcomes

IOP at 12 months after surgery. (Postopertive 12 months.)

Eligibility information

Inclusion Criteria: 1. 40 ≤ Age ≤ 85 years, gender unrestricted. 2. Diagnosed with POAG. 3. Controlled IOP under 1 to 4 topical hypotensive medications, IOP ≤ 24 mmHg 4. Mean deviation (MD) for perimetry ≥ -16dB. 5. Presence of clinically significant cataract and best-corrected visual acuity measured using the ETDRS chart ≤ 0.63. 6. Voluntary participation of the patient in this study, signing an informed consent form, and agreeing to follow-up visits according to the study protocol. Exclusion Criteria: 1. Any history of intraocular surgery or ocular trauma. 2. Presence of other types of glaucoma, including primary angle-closure glaucoma and various forms of secondary glaucoma (e.g. secondary angle-closure, pigmentary, steroid-induced, angle-recession, neovascular, inflammatory, and pseudoexfoliation syndrome). 3. Presence of severe ocular diseases of various types that affect the acquisition of ocular parameters or interfere with perimetry. 4. Axial length \> 28 mm. 5. Monophthalmia (best-corrected visual acuity of the non-study eye \< 0.01). 6. Coexistence of severe systemic diseases affecting the entire body. 7. Pregnant or lactating women. * If both eyes of a patient meet the criteria, the eye with worse visual acuity will be selected for inclusion.

Study locations

Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong 510060 China

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-29.